How a $2 Cough Syrup Exposed the Broken Economics of Mental Health

The Accidental Glimpse: Over-the-Counter Epiphanies and the Gateway to Clarity

For an individual navigating the debilitating realities of an eighteen-year major depressive episode, the sudden experience of a “Delsym afterglow” represents a profound moment of unexpected cognitive recovery. This phenomenon is not a recreational high, but rather a temporary, accidental alignment of brain chemistry. In these rare instances, a chronic psychiatric sufferer is inadvertently self-medicating a highly specific, historically neglected neurological pathway.¹ The subsequent commercialization of this simple chemical combination into Auvelity—a branded oral antidepressant costing upward of $1,200 per month—illustrates a fundamental systemic failure of American health economics.² It represents a healthcare machine designed to gatekeep widely available, inexpensive compounds in order to extract massive financial capital from chronic human suffering.²

The dominant narrative of chronic clinical depression has been controlled by the monoamine hypothesis for over sixty years, a paradigm that has dictated psychiatric treatment protocols with limited success.⁶ For those who fail to find relief within this rigid framework, discovering rapid clinical improvement via an over-the-counter cough suppressant is both a revelation and a profound indictment of modern medicine.⁶ It reveals that the biochemical keys to cognitive liberty have been sitting on drugstore shelves for decades, packaged as common cold remedies.⁷ The subsequent corporate financialization of this molecular pairing highlights the deep chasm between therapeutic innovation and economic accessibility in the United States.³

The Neurochemical Hack: Glutamate Pathways and the Monoamine Monopoly

Traditional psychiatry has spent more than half a century fixated on the slow-burn modulation of serotonin and norepinephrine.⁶ Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) remain the primary first-line therapies, yet they carry a staggering clinical failure rate.⁶ Approximately 60% to 70% of patients experience an inadequate therapeutic response to initial monoaminergic treatments.⁶ Furthermore, these traditional drugs operate on a delayed timeline, often requiring several weeks or months to yield therapeutic benefits, leaving severely depressed patients in prolonged states of vulnerability.

The emergence of glutamatergic modulation represents a major paradigm shift in critical psychopharmacology.¹ In vivo studies demonstrate that abnormal glutamate levels are highly prevalent among patients with Major Depressive Disorder (MDD).¹ Rather than slowly adjusting monoamine concentrations at the synaptic cleft, targeting the N-methyl-D-aspartate (NMDA) receptor—an ionotropic glutamate receptor—promotes rapid synaptic plasticity.² This mechanism essentially rewires the brain’s distress pathways, fostering rapid synaptogenesis and offering clinical improvement within days rather than weeks.¹

Dextromethorphan acts as an uncompetitive NMDA receptor antagonist and a sigma-1 receptor agonist.¹ However, as a standalone oral agent, its antidepressant potential is severely limited by rapid first-pass hepatic metabolism.¹ Dextromethorphan is a primary substrate of the cytochrome P450 2D6 (CYP2D6) liver enzyme, which rapidly degrades it into its metabolite, dextrorphan, preventing the drug from sustaining therapeutic concentrations in the central nervous system.¹

To bypass this metabolic barrier, pharmaceutical design utilizes a highly strategic pharmacokinetic workaround known as the “Kinetic Boost”.² By pairing dextromethorphan with bupropion—an aminoketone antidepressant that acts as a potent CYP2D6 inhibitor—the metabolic off-ramp is blocked.¹ Bupropion slows down the degradation of dextromethorphan, leading to a massive, nonlinear increase in its plasma concentration and extending its half-life.¹ At steady state, the accumulation ratios for dextromethorphan co-administered with bupropion are 20-fold for peak plasma concentration () and 32-fold for the area under the curve () compared to dextromethorphan administered alone.¹ This enzyme inhibition trick turns a common, cheap cough suppressant into a highly bioavailable, rapid-acting psychological liferaft.²

The efficacy of this combination was demonstrated in the Phase 2 ASCEND trial and the Phase 3 GEMINI trial.¹ The GEMINI trial evaluated 327 patients with moderate-to-severe MDD and showed statistically significant improvement in Montgomery-Åsberg Depression Rating Scale (MADRS) scores as early as Week 1, continuing through Week 6, compared to placebo.¹ Given that a change of approximately 2 points is the accepted Minimal Clinically Important Difference (MCID) on the MADRS, the therapeutic effects of the combination surpassed clinical benchmarks.¹

Additionally, the Clinical Global Impression-Improvement (CGI-I) scale showed that significantly more patients taking the combination were very much or much improved at Week 1 compared to placebo (22% vs 13%, P=0.035).¹ Long-term safety was further evaluated in the open-label COMET trial, which monitored 1,114 patients and noted common adverse reactions such as dizziness, headache, diarrhea, somnolence, dry mouth, sexual dysfunction, and hyperhidrosis.¹

While the dextromethorphan-bupropion combination successfully initiates the rapid-acting “NMDA spark,” its downstream molecular effects differ significantly from more potent NMDA antagonists like intravenous ketamine.² Ketamine initiates its antidepressant cascade through a precise sequence, beginning with the selective blockade of NMDA receptors on inhibitory GABAergic interneurons.² This disinhibits excitatory pyramidal neurons, causing a burst of glutamate release that is funneled through postsynaptic AMPA receptors.² This shift to an “AMPA-dominated” state triggers a calcium influx, prompting the release of Brain-Derived Neurotrophic Factor (BDNF) and activating the mammalian target of rapamycin (mTOR) pathway, which drives rapid protein synthesis, dendritic spine growth, and structural synaptogenesis.²

The dextromethorphan-bupropion combination replicates only the initial phase of this cascade.² Dextromethorphan blocks the NMDA receptor, but neither it nor bupropion possesses intrinsic AMPA-potentiating action.² Because the combination supplies the “NMDA spark” without the secondary “AMPA fuel,” its downstream activation of the BDNF and mTOR pathways is less robust.² This pharmacological gap explains why the therapeutic benefits of the oral combination arrive more slowly and fade more quickly than those of intravenous ketamine, highlighting the clinical limitations of this oral alternative.²

Pharmacological Parameter	Dextromethorphan-Bupropion (Auvelity)	Intravenous Ketamine
Primary Target Mechanism	Uncompetitive NMDA receptor antagonist & Sigma-1 agonist ¹	High-affinity uncompetitive NMDA receptor antagonist ²
Pharmacokinetic Profile	CYP2D6 inhibition via bupropion prolongs oral bioavailability ¹	Bypasses first-pass metabolism via intravenous or intranasal delivery ²
GABA Interneuron Disinhibition	Moderate initial receptor blockade ²	Rapid, potent receptor blockade ²
AMPA Receptor Potentiation	No direct or secondary AMPA augmentation ²	Strong secondary AMPA activation via glutamate surge ²
BDNF & mTOR Activation	Limited downstream synaptogenesis ²	Rapid, robust dendritic spine growth & circuit repair ²
Onset of Antidepressant Effect	Observable within 1 week ¹	Observable within hours ²
Durability of Therapeutic Benefit	Shorter duration; requires continuous daily dosing ²	Highly durable; sustained remodeling after single infusion ²

The $1,200 Paywall: The Corporate Extraction of Relief

The business model of modern psychopharmacology is clearly demonstrated by the development of Auvelity.⁶ Axsome Therapeutics did not discover a novel chemical entity; instead, they combined two off-patent, widely available, and inexpensive molecules.² Bupropion has been widely prescribed as an antidepressant since the 1980s, and dextromethorphan has been sold over-the-counter as a cough suppressant for over half a century.² By securing a patent on this specific fixed-dose ratio (45 mg dextromethorphan / 105 mg bupropion), the manufacturer established a monopoly, attaching a massive price premium to a combination of substances that cost pennies to manufacture.² Brand-name Auvelity retail pricing sits between $1,141 and $1,212 for a monthly supply of 60 tablets, representing a massive markup compared to the cost of its individual generic components.³

For low-income, vulnerable, or elderly patients enrolled in Medicare Advantage or managed care plans, accessing branded NMDA-targeting medications requires navigating a complex web of utilization management.¹¹ Insurers routinely employ two primary defensive cost-containment strategies: Prior Authorization (PA) and Step Therapy (ST).¹¹ Step therapy, often termed “fail-first” protocols, mandates that a patient must try and document clinical failure on a series of cheaper, preferred generic alternatives before the insurer will authorize coverage for a more expensive branded drug.¹²

In the case of Auvelity, major insurers enforce strict step-therapy guidelines.¹² Formularies routinely require the patient to have tried and failed at least two, and often three, preferred generic antidepressants from different classes—such as SSRIs, SNRIs, mirtazapine, or standalone generic bupropion—each for a minimum of 30 to 45 days.¹⁵ Furthermore, prior authorization criteria require explicit documentation of a Major Depressive Disorder diagnosis, age restrictions ( years), and the absence of clinical contraindications.¹⁶

These contraindications represent serious physiological hazards.¹⁸ Auvelity is strictly contraindicated in patients with seizure disorders or a history of bulimia or anorexia nervosa due to the increased seizure risk associated with bupropion.¹⁶ It is also contraindicated during abrupt discontinuation of alcohol, benzodiazepines, barbiturates, or antiepileptic drugs.¹⁶

Furthermore, serious drug interactions require close clinical monitoring.⁹ Co-administration with dopaminergic agents like levodopa or amantadine increases the risk of central nervous system toxicity, causing restlessness, tremor, ataxia, gait disturbance, and vertigo.⁹ Concomitant use with Monoamine Oxidase Inhibitors (MAOIs) is strictly contraindicated due to the risk of hypertensive crisis and serotonin syndrome.⁹

These metabolic and safety risks necessitate significant dosage adjustments.¹ The standard dose must be reduced to a single tablet daily in patients identified as poor CYP2D6 metabolizers, those with moderate renal impairment (eGFR 30 to 59 mL/minute/1.73 ), or when co-administered with strong CYP2D6 inhibitors.¹

Faced with a $1,200 paywall and restrictive insurance policies, a growing number of patients and clinicians have turned to a clinical workaround: the deconstructed generic combination.³ This “DIY combo” involves co-administering generic prescribed bupropion (typically 100 mg to 150 mg of the sustained-release or extended-release formulation) alongside precise, calculated doses of over-the-counter dextromethorphan hydrobromide tablets or liquid.³ This deconstructed approach bypasses the corporate paywall entirely, reducing the monthly cost of treatment from over $1,200 to less than $25.³ Within critical psychopharmacology, this practice is increasingly viewed as a form of medical mutual aid and economic survival, allowing patients to exercise cognitive liberty without incurring catastrophic debt.³

Regimen Formulation	Active Chemical Composition	Monthly Out-of-Pocket Cost (No Insurance)	Formulary Barriers & Clinical Restrictions
Branded Auvelity	Co-formulated Dextromethorphan HBr (45mg) / Bupropion HCl (105mg) ⁶	$1,141.26 – $1,212.74 ³	Subject to Step Therapy (requires failing 2-3 generic antidepressants) and Prior Authorization ¹⁵
Generic Wellbutrin XL	Bupropion Hydrochloride Extended-Release (150mg or 300mg) ³	$7.29 – $10.80 ³	Tier 1/2 Preferred Generic; minimal formulary restrictions ³
Generic OTC Cough Suppressant	Standalone Dextromethorphan Hydrobromide (liquid or tablet) ⁷	$9.53 – $9.99 ⁷	None; direct over-the-counter cash purchase ⁷
Deconstructed DIY Combination	Prescribed generic Bupropion + Over-the-Counter DXM ³	$16.82 – $20.79 ³	Requires patient-led self-dosing and clinical coordination ³
International Generic (Bupron DX)	Indian co-formulated Dextromethorphan HBr / Bupropion HCl ⁵	$134.40 – $137.40 ($4.48–$4.58 per tablet) ⁵	Requires import from verified international online pharmacies ⁵
Direct-to-Consumer Telehealth	Standard generic Bupropion via specialized platforms ⁸	$25.00 (with 3-month commitment) ⁸	Cash-only subscription model; circumvents standard insurance networks ⁸

The 2026 Political Paradox: Populist Rhetoric vs. Structural Neglect

The current political landscape of 2026 highlights a sharp contrast in American healthcare policy, where high-profile populist rhetoric on drug pricing clashes directly with the systematic dismantling of the healthcare safety net. On one hand, the Trump administration has engaged in highly visible efforts to address drug costs. On May 18, 2026, the administration announced a major expansion of the TrumpRx.gov price transparency platform.¹⁹ Originally launched on February 5, 2026, to host negotiated brand-name drug discounts, the expanded platform integrated over 600 generic medications via partnerships with Amazon Pharmacy, GoodRx, and Cost Plus Drugs.¹⁹

CMS Administrator Mehmet Oz, MD, and HHS Secretary Robert F. Kennedy Jr. have touted the portal as a revolutionary tool that bypasses insurance middlemen, encouraging patients to compare cash prices directly.¹⁹ Mehmet Oz, who was confirmed as CMS Administrator in April 2025 by a 53-45 party-line Senate vote, faced heavy scrutiny during his confirmation hearings regarding past advocacy for Medicare Advantage and financial ties to UnitedHealth Group.²² Despite these conflicts, Oz has continued to promote TrumpRx.gov as a major victory for consumer empowerment.²²

Additionally, on April 18, 2026, President Trump signed the executive order “Accelerating Medical Treatments for Serious Mental Illness,” directing federal agencies to fast-track clinical trials and regulatory reviews for psychedelic drugs like psilocybin, methylone, and ibogaine derivatives under the Right to Try Act.²³ On April 24, 2026, the FDA issued Commissioner’s National Priority Vouchers (CNPVs) to three companies studying psilocybin and methylone, and cleared a Phase I trial of noribogaine hydrochloride for alcohol use disorder.²³ The order also allocated $50 million via the Advanced Research Projects Agency for Health (ARPA-H) to support state research programs.²⁴

However, health policy analysts note that these initiatives are largely performative.²⁰ TrumpRx.gov operates primarily as a digital coupon aggregator.²⁰ It does not mandate structural price reductions on patented, high-cost drugs; indeed, brand-name medications on the site remain up to twice as expensive as in comparable wealthy nations.²⁰ Furthermore, the platform offers no financial relief for insured patients whose co-pays remain dictated by restrictive formularies.²⁰ The executive order fast-tracking experimental therapies does nothing to lower the costs of existing treatments, leaving patients to navigate a heavily financialized market.²³

While the administration promotes cost-transparency tools, the structural safety net that low-income and disabled psychiatric patients rely on is being significantly scaled back. The passage of the One Big Beautiful Bill Act (OBBBA) has introduced historic, long-term cuts to the Medicaid program.²⁹ According to a comprehensive analysis by the Rand Corporation, the law is projected to cut state Medicaid budgets by $664 billion between 2025 and 2034, while the Congressional Budget Office (CBO) estimates a federal Medicaid spending reduction of over $900 billion over the same period.²⁹

The OBBBA achieves these savings through structural changes, including mandated 80-hour monthly work, community service, or education requirements for adult enrollees starting January 1, 2027, and semi-annual eligibility redeterminations every six months.²⁹ The law also eliminates the 5% matching fund incentive for states to adopt Medicaid expansion under the American Rescue Plan Act, and limits states’ use of provider taxes and state-directed payments to fund their share of the program.²⁹

The CBO and health policy organizations estimate that these changes will increase the number of uninsured Americans by 7.5 to 7.8 million people.²⁹ The impact is highly concentrated, with states like California and New York facing massive budget reductions ($112 billion and $63 billion, respectively), and enrollment projected to drop by more than 20% in West Virginia, New Mexico, Oregon, and Washington, D.C..²⁹ For chronically depressed and vulnerable individuals, losing Medicaid eligibility means losing access to psychiatric care, medication coverage, and community-based support.²⁹

In parallel with these structural cuts, the Department of Health and Human Services (HHS) and the Substance Abuse and Mental Health Services Administration (SAMHSA) launched a campaign to address “psychiatric overprescribing”.²⁷ Announced on May 4, 2026, this initiative is framed in the language of patient autonomy, shared decision-making, and clinical caution.²⁷ The agency’s “Dear Colleague” letter encourages clinicians to regularly review medication regimens and prioritize “deprescribing” or tapering when clinical indicators are met, emphasizing non-pharmacological alternatives such as psychotherapy, nutritional strategies, and sleep hygiene.³⁴ To support this, the 2026 Physician Fee Schedule introduced specific billing codes allowing providers to bill Medicare and Medicaid for tapering or discontinuing psychiatric medications.³⁴

While clinical caution and tapering are appropriate in many cases, health policy analysts and professional mental health organizations warn that this campaign may serve as a convenient justification for cost-cutting.²⁷ Under a heavily defunded Medicaid system, a federal push for deprescribing and non-pharmacological care can function as a pretext to deny coverage for expensive, branded psychiatric therapies like Auvelity.²⁷ Telling a low-income patient to pursue psychotherapy or lifestyle changes as an alternative to medication is often impractical when community mental health clinics face severe workforce shortages and long waitlists.²⁷ By promoting “non-pharmacological” care without funding the community infrastructure to provide it, the state shifts the burden of mental illness back onto the individual, masking systemic disinvestment under the guise of clinical wellness.²⁷

Policy Domain	Rhetorical and Consumer Initiatives (2026)	Structural Retrenchment & Safety Net Cuts (OBBBA)
Primary Legislation / Policy	TrumpRx.gov drug portal & Psychedelic Executive Order ¹⁹	One Big Beautiful Bill Act (OBBBA) / S. 2 Reconciliation ²⁹
Operational Mechanism	Voluntary price-comparison database; expedited FDA priority vouchers ²⁰	80-hour monthly work mandates; 6-month eligibility checks; provider tax caps ²⁹
Financial Impact	Connects cash-paying patients to drug discounts; does not lower brand list prices ¹⁹	State Medicaid budgets cut by $664B; federal spending cut by $911B over 10 years ²⁹
Prescribing & Clinical Directives	Accelerates experimental access pathways under the Right to Try Act ²⁴	SAMHSA “MAHA” campaign to curb psychiatric overprescribing and promote tapering ²⁷
Impact on Vulnerable Patients	Limited to affluent cash-paying consumers; partisan branding reduces usage ²⁰	Projected coverage loss for 7.5M to 7.8M low-income Americans ²⁹
Primary Critique	Operates as performative medicine without addressing structural drug pricing ²⁰	Leverages clinical “deprescribing” guidelines as a pretext for safety-net disinvestment ²⁷

Conclusion: Demanding Cognitive Liberty

The intersection of neurobiology, corporate finance, and public policy highlights the structural issues within the American mental health system. The discovery that a $2 over-the-counter cough suppressant can rapidly lift an 18-year depressive fog reveals that effective treatments have long been within reach.³ Yet, the financialization of this discovery—resulting in a $1,200 monthly paywall—demonstrates how corporate patent structures can restrict access to existing, cheap molecules.³

At the same time, the 2026 political landscape presents a stark contradiction.²⁰ Performative, consumer-focused initiatives like TrumpRx.gov are heavily promoted, while the foundational safety nets that low-income and disabled patients rely on are systematically scaled back through historic cuts to Medicaid.²⁰ The federal emphasis on “deprescribing” and non-pharmacological care, while framed as patient-centered, risks being used to justify denying access to effective pharmacological treatments within a resource-constrained system.²⁷

Chronically depressed patients should not have to function as self-taught biohackers, navigating complex pharmacology and compounding generic workarounds just to achieve basic cognitive stability.³ True mental health reform requires moving beyond digital coupon portals and addressing the root causes of high drug prices.²⁰ This demands challenging the arbitrary patent structures that allow pharmaceutical companies to monopolize and markup combinations of existing, off-patent molecules.⁵ It also requires opposing structural cuts to Medicaid to ensure low-income and disabled individuals maintain reliable access to care.²⁹ True cognitive liberty cannot be achieved through performative public platforms; it requires a healthcare system that prioritizes human well-being over corporate capital extraction.⁶

Works cited

Auvelity: A Rapid-Acting Antidepressant With Multimodal Activity | Psychiatrist.com, accessed June 4, 2026, https://www.psychiatrist.com/auvelity-rapid-acting-antidepressant-with-multimodal-activity/
DXM, CYP2D6-Inhibiting Antidepressants, Piracetam, and …, accessed June 4, 2026, https://www.preprints.org/manuscript/202511.1815
Auvelity vs. Wellbutrin XL: Which Is a Better Treatment for Depression? – GoodRx, accessed June 4, 2026, https://www.goodrx.com/conditions/depression/auvelity-vs-wellbutrin-xl
Auvelity vs. Wellbutrin XL for Depression: Important Differences and Potential Risks., accessed June 4, 2026, https://www.goodrx.com/compare/auvelity-vs-wellbutrin
Dextromethorphan Hydrobromide/Bupropion Hydrochloride Prescription – Buy Online and Save – Universal Drugstore, accessed June 4, 2026, https://www.universaldrugstore.com/medications/dextromethorphan-hydrobromide-bupropion-hydrochloride
Rapid-acting oral drug (Auvelity) for major depressive disorder – PMC – NIH, accessed June 4, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC9577655/
Auvelity vs Dextromethorphan Comparison – Drugs.com, accessed June 4, 2026, https://www.drugs.com/compare/auvelity-vs-dextromethorphan
Auvelity vs. Wellbutrin (Bupropion): How Do They Compare? | RedBox Rx, accessed June 4, 2026, https://www.redboxrx.com/blog/auvelity-vs-wellbutrin-bupropion-a-complete-guide
Drugs@FDA Drug Product: AUVELITY (dextromethorphan hydrobromide / bupropion hydrochloride) – ClinPGx, accessed June 4, 2026, https://www.clinpgx.org/literature/15135602
DXM, CYP2D6-inhibiting antidepressants, piracetam, and glutamine: proposing a ketamine-class antidepressant regimen with existing drugs – Frontiers, accessed June 4, 2026, https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2026.1751605/full
Prior Authorization, Step Therapy & Quantity Limitations | – Home State Health, accessed June 4, 2026, https://wellcare.homestatehealth.com/drug-pharmacy/prior-authorization.html
Prior Authorization and Step Therapy Coverage Criteria – BCBSM, accessed June 4, 2026, https://www.bcbsm.com/amslibs/content/dam/public/consumer/forms-documents/pharmacy/preferred-drug-list-prior-authorization-and-step-therapy-guidelines.pdf
Drug Formulary Tiers Explained: Step Therapy vs. PA Guide | IntuitionLabs, accessed June 4, 2026, https://intuitionlabs.ai/articles/drug-formulary-tiers-step-therapy-prior-authorization
Prescription Drug Guide – Humana Formulary, accessed June 4, 2026, https://assets.humana.com/is/content/humana/20260015PDG2640826Cpdf
Step Therapy Utilization Management Commercial – BCBSND, accessed June 4, 2026, https://www.bcbsnd.com/content/dam/bcbsnd/documents/pharmacy/restricted-step-therapy.pdf
AUVELITY (dextromethorphan hydrobromide, bupropion hydrochloride) – http://www.westernhealth.com, accessed June 4, 2026, https://www.westernhealth.com/provider/prior-authorization-archive/auvelity-dextromethorphan-hydrobromide-bupropion-hydrochloride/
Clinical Guideline Auvelity (Dextromethorphan and Bupropion), accessed June 4, 2026, https://assets.ctfassets.net/plyq12u1bv8a/ugn6ojGBmNCbm9fPwWLzV/723c7e377f80dd74a26f4c404b826197/PG128_Auvelity__Dextromethorphan_and_Bupropion__v3.pdf
CP.PMN.284 Dextromethorphan-bupropion (Auvelity) – Health Net, accessed June 4, 2026, https://www.healthnet.com/content/dam/centene/policies/pharmacy-policies/pmn/CP.PMN.284.pdf
Fact Sheet: President Donald J. Trump Announces Expansion of TrumpRx.gov to Bring Americans Transparency and Choice on Everyday Medicines, accessed June 4, 2026, https://www.whitehouse.gov/fact-sheets/2026/05/fact-sheet-president-donald-j-trump-announces-expansion-of-trumprx-gov-to-bring-americans-transparency-and-choice-on-everyday-medicines/
TrumpRx – Wikipedia, accessed June 4, 2026, https://en.wikipedia.org/wiki/TrumpRx
TrumpRX: White House unveils expansion of discounted-drug website, accessed June 4, 2026, https://www.youtube.com/watch?v=RLreGTDwVpo&vl=en
Oz White House Briefing Touts Drug Savings and Fraud Cleanup, but Data Tell a Nuanced Story, accessed June 4, 2026, https://www.ajmc.com/view/oz-white-house-briefing-touts-drug-savings-and-fraud-cleanup-but-data-tell-a-nuanced-story
Trump Administration Shifts Policy to Accelerate Access to Psychedelic Drugs for Mental Illness – Latham & Watkins, accessed June 4, 2026, https://www.lw.com/en/insights/trump-administration-shifts-policy-to-accelerate-access-to-psychedelic-drugs-for-mental-illness
Executive Order Expands Psychedelic Research Access – Recovered.org, accessed June 4, 2026, https://recovered.org/blog/trump-eo-psychedelic-treatment-research-expansion
Trump’s psychedelic executive order: president expands access to psychoactive drugs, accessed June 4, 2026, https://www.bmj.com/content/393/bmj.s794
FDA Accelerates Action on Treatments for Serious Mental Illness Following Executive Order, accessed June 4, 2026, https://www.fda.gov/news-events/press-announcements/fda-accelerates-action-treatments-serious-mental-illness-following-executive-order
Tracking Key Mental Health and Substance Use Policy Actions Under the Trump Administration | KFF, accessed June 4, 2026, https://www.kff.org/mental-health/tracking-key-mental-health-and-substance-use-policy-actions-under-the-trump-administration/
You Are Not Hallucinating: Executive Order Aims to Accelerate Approval of Therapeutic Psychedelics – Morgan Lewis, accessed June 4, 2026, https://www.morganlewis.com/pubs/2026/04/you-are-not-hallucinating-executive-order-aims-to-accelerate-approval-of-therapeutic-psychedelics
State Medicaid budgets face $664B cut due to ‘Big Beautiful Bill …, accessed June 4, 2026, https://www.healthcaredive.com/news/state-medicaid-budget-cuts-one-big-beautiful-bill-act-rand/813663/
Kennedy Denies the One Big Beautiful Bill Act’s Spending Cuts to Medicaid – FactCheck.org, accessed June 4, 2026, https://www.factcheck.org/2026/05/kennedy-denies-the-one-big-beautiful-bill-acts-spending-cuts-to-medicaid/
CMS releases Medicaid work requirements guidance for states, accessed June 4, 2026, https://www.healthcaredive.com/news/cms-medicaid-work-requirements-final-rule-state-guidance/821631/
President Trump’s “One Big Beautiful Bill” Makes Changes to Medicaid, accessed June 4, 2026, https://www.crowell.com/en/insights/client-alerts/president-trumps-one-big-beautiful-bill-makes-changes-to-medicaid
HHS announces action plan on psychiatric ‘overprescribing’ | AHA News, accessed June 4, 2026, https://www.aha.org/news/headline/2026-05-05-hhs-announces-action-plan-psychiatric-overprescribing
HHS to Attack Overprescribing of Psychiatric Drugs – Alliance of Safety-Net Hospitals, accessed June 4, 2026, https://safetynetalliance.org/hhs-to-attack-overprescribing-of-psychiatric-drugs/
DCL Psychiatric Medication Non-Pharmacological … – SAMHSA, accessed June 4, 2026, https://www.samhsa.gov/sites/default/files/dcl-psychiatric-medication-nonpharmacological-treatments.pdf
HHS Announces Plan to Limit Psychiatric Overprescribing – America’s Essential Hospitals, accessed June 4, 2026, https://essentialhospitals.org/hhs-announces-plan-to-limit-psychiatric-overprescribing/
Senate Clears Path for Historic Tax Cut Bill, accessed June 4, 2026, https://legis1.com/news/senate-tax-cut-bill-clears-path-for-historic-and